Analysts expect Evolent Health, Inc. (NYSE:EVH) to report $-0.10 EPS on May, 8.They anticipate $0.16 EPS change or 61.54% from last quarter’s $-0.26 EPS. After having $-0.10 EPS previously, Evolent Health, Inc.’s analysts see 0.00% EPS growth. It closed at $15.7 lastly. It is down 34.82% since April 14, 2017 and is downtrending. It has underperformed by 46.37% the S&P500.
Globus Medical Inc Class A (NYSE:GMED) had a decrease of 14.36% in short interest. GMED’s SI was 3.74 million shares in April as released by FINRA. Its down 14.36% from 4.37M shares previously. With 631,100 avg volume, 6 days are for Globus Medical Inc Class A (NYSE:GMED)’s short sellers to cover GMED’s short positions. The SI to Globus Medical Inc Class A’s float is 5.33%. The stock increased 0.06% or $0.03 during the last trading session, reaching $50.66. About 332,785 shares traded. Globus Medical, Inc. (NYSE:GMED) has risen 65.36% since April 14, 2017 and is uptrending. It has outperformed by 53.81% the S&P500.
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides healthcare delivery and payment solutions in the United States. The company has market cap of $1.22 billion. It operates as a managed services firm that supports integrated health systems in migration toward value care and population health management. It currently has negative earnings. The company's services include providing clients with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services, and comprehensive health plan administration services.
Among 14 analysts covering Evolent Health (NYSE:EVH), 14 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Evolent Health had 40 analyst reports since August 7, 2015 according to SRatingsIntel. KeyBanc Capital Markets initiated it with “Buy” rating and $23.0 target in Tuesday, September 19 report. The rating was maintained by Robert W. Baird with “Outperform” on Thursday, September 28. The stock of Evolent Health, Inc. (NYSE:EVH) has “Buy” rating given on Wednesday, June 14 by Robert W. Baird. The stock has “Buy” rating by Jefferies on Tuesday, February 13. The stock of Evolent Health, Inc. (NYSE:EVH) earned “Buy” rating by Oppenheimer on Wednesday, June 21. The rating was maintained by Cantor Fitzgerald on Wednesday, August 9 with “Buy”. The firm earned “Buy” rating on Sunday, September 24 by Robert W. Baird. The company was maintained on Thursday, November 16 by Leerink Swann. On Tuesday, January 2 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The stock of Evolent Health, Inc. (NYSE:EVH) earned “Buy” rating by Canaccord Genuity on Wednesday, January 6.
Among 15 analysts covering Globus Medical Inc (NYSE:GMED), 10 have Buy rating, 2 Sell and 3 Hold. Therefore 67% are positive. Globus Medical Inc had 48 analyst reports since August 3, 2015 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Friday, May 5. The stock has “Underweight” rating by Barclays Capital on Thursday, October 19. Leerink Swann downgraded the shares of GMED in report on Wednesday, July 27 to “Market Perform” rating. The rating was upgraded by Morgan Stanley on Tuesday, January 2 to “Overweight”. The stock of Globus Medical, Inc. (NYSE:GMED) has “Buy” rating given on Thursday, January 4 by Canaccord Genuity. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, January 9. Piper Jaffray maintained Globus Medical, Inc. (NYSE:GMED) rating on Thursday, February 22. Piper Jaffray has “Buy” rating and $54.0 target. The firm has “Mkt Perform” rating given on Wednesday, November 9 by JMP Securities. As per Thursday, March 23, the company rating was maintained by Oppenheimer. The firm earned “Underweight” rating on Thursday, November 9 by Barclays Capital.
Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company has market cap of $4.90 billion. The firm offers products that address an array of spinal pathologies, anatomies, and surgical approaches. It has a 46.05 P/E ratio. It provides fusion products that are used in cervical, thoracolumbar, sacral, and interbody/corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions.